New drug offers hope for hard-to-treat lymphomas
NCT ID NCT05891821
First seen Jun 12, 2026 · Last updated Jun 12, 2026
Summary
This study tests whether the drug balstilimab is safe and can shrink tumors in people with certain lymphomas (Hodgkin or primary mediastinal B-cell) that have returned or not responded to standard treatments. About 20 adults will receive the drug every 3 weeks. The main goal is to see how many patients have their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hematology Center named after prof. R. Yeolyan
RECRUITINGYerevan, 0014, Armenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.